Why Amgen Shares Are Trading Lower Today

Amgen Inc AMGN reported Q1 FY23 sales of $6.11 billion, down 2% Y/Y, resulting from lower revenue from COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. The consensus estimate stood at $6.17 billion.

Product sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels, and 2% negative impact from foreign exchange. 

Excluding the 2% negative impact of foreign exchange on product sales, total revenues were largely unchanged from Q1 2022.

Related: Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B.

Adjusted EPS decreased 6% to $3.98, beating the consensus of $3.85.

Pipeline Update: On the chopping block at Amgen is a study of rozibafusp alfa, formerly dubbed AMG 570, a Phase 2b study for systemic lupus erythematosus has been stopped “for futility.”

The other immunology program to be cut is a separate phase 2b study of efavaleukin alfa, formerly AMG 592. The interleukin-2 (IL-2) mutein Fc fusion protein was also being assessed in SLE in a Phase 2b study for futility. 

Amgen continues to evaluate the IL-2 drug in a mid-stage trial for ulcerative colitis.

Guidance: Amgen expects FY23 revenue of $26.2-$27.3 billion compared to the consensus of $26.7 billion, with adjusted EPS of $17.60-$18.70 versus the Wall Street estimate of $17.72.

Price Action: AMGN shares are down 2.23% at $234.99 premarket on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!